INTRAVITREAL INJECTION OF 2.5 mg VERSUS 1.25 mg BEVACIZUMAB (AVASTIN) FOR TREATMENT OF CNV ASSOCIATED WITH AMD

Title
INTRAVITREAL INJECTION OF 2.5 mg VERSUS 1.25 mg BEVACIZUMAB (AVASTIN) FOR TREATMENT OF CNV ASSOCIATED WITH AMD
Authors
Keywords
-
Journal
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2009-05-22
DOI
10.1097/iae.0b013e318198148e

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started